Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5912132 | Multiple Sclerosis and Related Disorders | 2016 | 10 Pages |
Abstract
We here report a case involving a 38-year-old female with relapsing and remitting multiple sclerosis who developed reactivation of hepatitis C virus (HCV) during administration of fingolimod for 16 months. She had been previously treated for chronic hepatitis C with pegylated interferon and ribavirin, and kept an undetectable HCV-RNA state for more than 4 years before fingolimod starting. Although the increased risk for viral reactivation, for example of herpes zoster virus and varicella-zoster virus, during fingolimod treatment is known, this is, to our knowledge, the first case report of HCV reappearance.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Genetics
Authors
Asako Tagawa, Tomoko Ogawa, Syuichi Tetsuka, Mieko Otsuka, Ritsuo Hashimoto, Hiroyuki Kato, Katsuyoshi Ando, Hiroki Tanabe,